Dr. Reddy’s launches Minoxidil for treatment of female pattern hair loss
Dr. Reddy’s Laboratories said that it has launched a prescription drug for the treatment of female pattern hair loss (FPHL) in the form of Minoxidil topical solution USP 2% and 5% in India.
The Indian pharma company will sell the female pattern hair loss treatment under the brand names Mintop 2% and Mintop Eva 5%, respectively.
According to Dr. Reddy’s Laboratories, the launch of Minoxidil topical solution USP 2% and 5% follows the first-ever approval of the additional indication from India’s Central Drugs Standard Control Organization (COSCO) for the treatment of female pattern hair loss.
The Indian pharma giant said that Minoxidil topical solution will be available as first-line treatment option for the hair loss condition in India.
Dr. Reddy’s Laboratories added that although Minoxidil topical solution has been approved in India for the treatment of male pattern baldness in men, currently there are no other drugs approved for the treatment of female pattern hair loss treatment in the country.
M.V. Ramana — CEO of Dr. Reddy’s Laboratories Branded Markets (India & Emerging Markets) said: “This approval marks the first-ever given to a first-line treatment option for female pattern hair loss, and truly fulfils a hitherto unmet need.
“Our Minoxidil topical solution (Mintop 2% & Mintop Eva 5%) for women will be widely available in the country, and through this launch, we hope to bring relief and comfort to patients diagnosed with FPHL in India.”
Recently, Dr. Reddy’s Laboratories signed a deal worth up to $150 million to offload its rights to E7777, an engineered IL-2-diphtheria toxin fusion protein, and certain related assets to Citius Pharmaceuticals.